Comment from California Institute for Regenerative Medicine

Summary: The California Institute for Regenerative Medicine (CIRM), a state agency, supports the draft guidance as a positive regulatory innovation for accelerating the development of genetic medicines for rare diseases. They advocate for specific refinements, including clearer eligibility criteria, flexibility in observational periods for rapidly progressing diseases, and the creation of a unique regulatory designation to ensure consistent FDA interaction.